NCT02908035 (TANGO) is a Phase 2 clinical trial of Temsirolimus in Chronic Limb Ischemia, sponsored by Mercator MedSystems, Inc..

Who is sponsoring NCT02908035?

NCT02908035 is sponsored by Mercator MedSystems, Inc..

What drugs are being tested in NCT02908035?

Interventions in NCT02908035: Temsirolimus, Saline.

What condition does NCT02908035 study?

NCT02908035 studies Chronic Limb Ischemia.

Is NCT02908035 still recruiting?

NCT02908035 is currently status unknown. Last updated 9 June 2020.

Last reviewed 2020-06-09 · How we verify

NCT02908035: TANGO

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

TANGO: Temsirolimus Adventitial Delivery to Improve ANGiographic Outcomes Below the Knee

Status unknown Phase 2 Last updated 9 June 2020

What this trial tests

Phase 2 trial testing Temsirolimus in Chronic Limb Ischemia in 100 participants. Status unknown.

Timeline

3 March 2017

Primary endpoint
1 September 2020

1 September 2021

Quick facts

Lead sponsor	Mercator MedSystems, Inc.
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	100
Start date	3 March 2017
Primary completion	1 September 2020
Estimated completion	1 September 2021
Sites	8 locations across United States

Drugs / interventions tested

Temsirolimus (temsirolimus) — full drug profile →
Saline

Conditions studied

Chronic Limb Ischemia — all drugs for Chronic Limb Ischemia →

Sponsor

Mercator MedSystems, Inc. — full company profile →

Who can join

Adults 18 to 90, any sex, with Chronic Limb Ischemia. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Freedom from MALE-POD
Time frame: Up to 30 days post-procedure
Freedome from MALE-POD at 30 days.
Transverse-view vessel area loss percentage (TVAL%) of the target lesion
Time frame: Within 6 months post-procedure
Transverse-view vessel area loss percentage (TVAL%) of the target lesion at 6 months by quantitative vascular angiography (QVA) or prior to any TLR of the target lesion before 6 months.

Sponsor's own description

This is a prospective, multi-center, randomized, dose escalation study to document the effects of adventitial delivery of temsirolimus (Torisel) after revascularization of lesions below the knee in symptomatic patients with critical limb ischemia (CLI).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Current developments in endovascular therapy of peripheral vascular disease.
Kokkinidis DG, Armstrong EJ. · · 2020 · cited 28× · PMID 32395311 · DOI 10.21037/jtd.2019.12.130

Verify or expand the search:

Other trials of Temsirolimus

Trials testing the same drug.

NCT04433572 — Temsirolimus Adventitial Delivery to Improve ANGioplasty and/or Atherectomy Revascularization Outcomes Below the Knee · Phase 3 · recruiting
NCT04199026 — Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sa · NA · recruiting
NCT03203525 — Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurre · Phase 1 · active not recruiting
NCT03942601 — Temsirolimus Alone or Paired With Dexamethasone Delivered to the Adventitia to eNhance Clinical Efficacy After Femoropop · Phase 2 · terminated
NCT03158389 — NCT Neuro Master Match - N²M² (NOA-20) · Phase 1, PHASE2 · completed

Other recruiting trials for Chronic Limb Ischemia

Currently open trials in the same condition.

NCT06416644 — The PORTuguese Registry of Supera Supported Femoral-Fopliteal Revascularization (SupPORT Registry) · NA · active not recruiting

Other Mercator MedSystems, Inc. trials

Trials by the same sponsor.

NCT04433572 — Temsirolimus Adventitial Delivery to Improve ANGioplasty and/or Atherectomy Revascularization Outcomes Below the Knee · Phase 3 · recruiting
NCT04858776 — Perivenous Dexamethasone Therapy: Examining Reduction of Inflammation After Thrombus Removal to Yield Benefit in Subacut · Phase 2 · recruiting
NCT04862468 — Perivenous Dexamethasone Therapy: Examining Reduction of Inflammation After Thrombus Removal to Yield Benefit in Acute F · Phase 2 · recruiting
NCT03942601 — Temsirolimus Alone or Paired With Dexamethasone Delivered to the Adventitia to eNhance Clinical Efficacy After Femoropop · Phase 2 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02908035 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Mercator MedSystems, Inc.
Last refreshed: 9 June 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02908035.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing